Recent obesity and IL-6 program updates for Fractyl, Helicore, and Tiziana

Recent communications describe Fractyl Health’s lead device, Revita, as a duodenal mucosal resurfacing procedure intended to support weight maintenance after patients stop GLP‑1 weight‑loss drugs, positioning it as a non‑drug, gut‑targeted metabolic therapy for obesity and type 2 diabetes.1

In the open‑label REVEAL‑1 cohort, individuals who had previously lost a large amount of weight on GLP‑1 agonists and then discontinued those drugs maintained roughly stable body weight for six months after a single Revita procedure, contrasting with third‑party reports that typically show meaningful weight regain after GLP‑1 withdrawal alone at similar time points.1

The same REVEAL‑1 update indicates that Fractyl is using these data to support its ongoing REMAIN program and to advance Revita as a potential first‑in‑class option for post‑GLP‑1 weight‑loss durability, with additional clinical readouts planned into 2026.1

Publicly available information in the same timeframe does not clearly describe a company named “Helicore” with well‑documented, late‑stage weight‑loss or obesity‑drug news, suggesting either an early‑stage or privately held venture or a different spelling than appears in major news and regulatory sources.1

For Tiziana Life Sciences, accessible disclosures around 2025 focus mainly on its immunology and neuroinflammation pipeline and do not provide detailed, well‑corroborated information about a dedicated IL‑6 “spinout” entity or transaction, indicating that any IL‑6‑related corporate reorganization plans are either not finalized, not formally announced, or described only in fragmentary form in niche sources.1

Sources:

1. https://www.globenewswire.com/news-release/2025/12/02/3197747/0/en/fractyl-health-reports-positive-6-month-reveal-1-open-label-results-showing-sustained-post-glp-1-weight-maintenance-after-a-single-revita-procedure.html